Gain Therapeutics (GANX) EBT Margin (2020 - 2023)
Gain Therapeutics (GANX) posted EBT Margin of 9279.8% for Q1 2023, down 73.85% on a QoQ basis from 5337.72% in Q2 2022, and down 201195.0% year-over-year from N/an in Q1 2022.
Powered by 
Analysis
Gain Therapeutics (GANX) EBT Margin (2020 - 2023) Analysis & Trends
Gain Therapeutics has reported EBT Margin for 4 years, with the latest figure at 9279.8% in Q1 2023.
- On a quarterly basis, EBT Margin fell 201195.0% year-over-year to 9279.8% in Q1 2023; TTM through Dec 2023 was 40735.22%, a 2824645.0% decrease from a year earlier, with the FY2023 full-year figure at 40735.22%, down 2824645.0% from the prior year.
- EBT Margin was 9279.8% for Q1 2023 at Gain Therapeutics, down from 5337.72% in the prior quarter.
- The five-year high for EBT Margin was 3984.43% in Q2 2021, with the low at 46440.84% in Q1 2021.
- Average EBT Margin over 4 years is 13089.99%, with a median of 8735.52% recorded in 2020.
- The sharpest annual moves came in 2021 and 2022: EBT Margin plunged 3770533 bps in 2021, then jumped 3917300 bps in 2022.
- Over 4 years, EBT Margin stood at 18131.62% in 2020, then surged by 59 bps to 7471.25% in 2021, then gained by 29 bps to 5337.72% in 2022, then plunged by 74 bps to 9279.8% in 2023.
- The last three EBT Margin figures came in at 9279.8% (Q1 2023), 5337.72% (Q2 2022), and 7267.84% (Q1 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -9,279.80% |
| Jun 30, 2022 | -5,337.72% |
| Mar 31, 2022 | -7,267.84% |
| Dec 31, 2021 | -7,471.25% |
| Sep 30, 2021 | -17,035.72% |
| Jun 30, 2021 | -3,984.43% |
| Mar 31, 2021 | -46,440.84% |
| Dec 31, 2020 | -18,131.62% |
| Sep 30, 2020 | -11,850.15% |
| Jun 30, 2020 | -8,455.03% |
| Mar 31, 2020 | -8,735.52% |